TRIANNI & the German Society for Immunology (DGfI) honors outstanding young scientists.
Every year, the German Society for immunology awards two doctoral and three early-career prizes to young scientists who have made an outstanding contribution in the field of immunology. The award ceremony took place during the 5th European Congress of Immunology in Amsterdam. TRIANNI was honored to sponsor one of the awards; The Werner-Müller Award.
Eva Kaufmann receives the prize for describing a new mechanism for protection against tuberculosis with the vaccine Mycobacterium bovis Bacillus Calmette-Guérin (BCG). Tuberculosis is an infectious disease caused by mycobacteria. With approximately 1.7 million deaths per year, the disease is one of the ten most frequent causes of death worldwide. BCG is so far the only tuberculosis vaccine approved worldwide. The vaccine consists of attenuated, non-infectious bovine tuberculosis bacteria that are used as live vaccines. It is known that macrophages play a decisive role in the defence against tuberculosis infections. Unfortunately, macrophages are only very short-lived. Therefore, vaccine strategies directly targeting macrophages would have only a limited effect on the generation of longterm immunological memory. In contrast to macrophages, their precursor cells, the hematopoietic stem cells (HSC) in the bone marrow, are very long-lived. HSC generate all cells of the blood system. Eva Kaufmann's work in the mouse model shows that the access of BCG to the bone marrow leads to a reprogramming of HSCs.
This leads to the formation of macrophages that provide improved protection against tuberculosis. These observations show that HSC represents new targets for vaccine development, and thus open up innovative prophylaxis approaches for tuberculosis and possibly other infectious diseases.
Organizations
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
4SC and Yakult Honsha Announce Exclusive License Agreement for Japan for the Oral HDAC Inhibitor Resminostat
Orphan drug designation for treatment against lung infections by Axentis Pharma AG
Abbott Opens Asia-Pacific Nutrition Research & Development Center in Singapore
Innovative Research on Manufacturing of Viral Vaccines and Gene Therapies - "Innovation Prize 2021 of the German BioRegions" awarded to ContiVir
